<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102576">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01990560</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 13-1061</org_study_id>
    <nct_id>NCT01990560</nct_id>
  </id_info>
  <brief_title>Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism</brief_title>
  <official_title>Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Sinai School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mount Sinai School of Medicine</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether mifepristone is an effective treatment for
      hyperglycemia due to mild hypercortisolism.

        -  To test the hypothesis that GR blockade with mifepristone will decrease the severity of
           metabolic syndrome features as measured by waist circumference, lipid profile, body
           mass index, blood pressure and insulin resistance, measured by HOMA-IR score.

        -  To test the hypothesis that GR blockade with mifepristone will improve QoL, depression
           and anxiety scores, measured by validated assessments, in patients with mild
           hypercortisolism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>hyperglycemia</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement in hyperglycemia - fasting glucose, HbA1c, HOMA-IR (a validated assessment of insulin resistance, HOMA-IR = (glucose md/dl x insulin mg/dl)/405)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic Syndrome</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement in metabolic syndrome - outcomes include cortisol, fasting lipid profile, weight, BMI (kg/m2), waist circumference (in centimeters), and blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement in Quality of Life - completion of 3 validated QoL questionnaires (Cushing's Quality of Life questionnaire (CushingQoL), Nottingham Health Profile (NHP), and Hospital Anxiety and Depression Scale (HADS)), and the visual analogue scale (VAS) to quantify appetite. Patients will also complete the Beck Depression Inventory and the State Trait Anxiety Inventory (STAI).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mild Hypercortisolism</condition>
  <arm_group>
    <arm_group_label>Mifepristone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mifepristone 300mg tablets taken once daily with dose increase of no more than 300mg once monthly and to a maximum dose of 1200mg daily as indicated by symptom response</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>All patients in the study will receive daily Mifepristone for 6 months and primary and secondary outcomes will be assessed before and after the 6 month treatment period</description>
    <arm_group_label>Mifepristone</arm_group_label>
    <other_name>Korlym</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years of age

          -  Incidentally noted adrenal nodule &lt;4 cm with benign imaging characteristics

          -  Evidence of mild hypercortisolism

          -  Evidence of diabetes or abnormal glucose tolerance

        Exclusion Criteria:

          -  contraindication to mifepristone

          -  Indication for unilateral adrenalectomy

          -  Evidence of other adrenal hormone hypersecretion

          -  lactating mothers

          -  women of childbearing age unwilling to use an effective, nonhormonal form of
             contraception
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice C Levine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gillian Goddard, MD</last_name>
    <phone>212-241-1500</phone>
    <email>Gillian.m.goddard@mssm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gillian Goddard, MD</last_name>
      <phone>212-241-1500</phone>
      <email>Gillian.m.goddard@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Alice C Levine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Young WF Jr. Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am. 2000 Mar;29(1):159-85, x. Review.</citation>
    <PMID>10732270</PMID>
  </reference>
  <reference>
    <citation>Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004 Apr;25(2):309-40. Review.</citation>
    <PMID>15082524</PMID>
  </reference>
  <reference>
    <citation>Tauchmanovà L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri EA, Fazio S, Lombardi G. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002 Nov;87(11):4872-8.</citation>
    <PMID>12414841</PMID>
  </reference>
  <reference>
    <citation>Terzolo M, Pia A, Alì A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G, Angeli A. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002 Mar;87(3):998-1003.</citation>
    <PMID>11889151</PMID>
  </reference>
  <reference>
    <citation>Garrapa GG, Pantanetti P, Arnaldi G, Mantero F, Faloia E. Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome. J Clin Endocrinol Metab. 2001 Nov;86(11):5301-6.</citation>
    <PMID>11701696</PMID>
  </reference>
  <reference>
    <citation>Feelders RA, Hofland LJ. Medical treatment of Cushing's disease. J Clin Endocrinol Metab. 2013 Feb;98(2):425-38. doi: 10.1210/jc.2012-3126. Epub 2013 Jan 23. Review.</citation>
    <PMID>23345100</PMID>
  </reference>
  <reference>
    <citation>Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, Geer EB. Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients. J Clin Endocrinol Metab. 2013 Mar;98(3):1022-30. doi: 10.1210/jc.2012-2893. Epub 2013 Feb 7.</citation>
    <PMID>23393167</PMID>
  </reference>
  <reference>
    <citation>Debono M, Chadarevian R, Eastell R, Ross RJ, Newell-Price J. Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study. PLoS One. 2013;8(4):e60984. doi: 10.1371/journal.pone.0060984. Epub 2013 Apr 5.</citation>
    <PMID>23577182</PMID>
  </reference>
  <reference>
    <citation>Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008 May;93(5):1526-40. Epub 2008 Mar 11.</citation>
    <PMID>18334580</PMID>
  </reference>
  <reference>
    <citation>Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48.</citation>
    <PMID>10702749</PMID>
  </reference>
  <reference>
    <citation>Parker BA, Sturm K, MacIntosh CG, Feinle C, Horowitz M, Chapman IM. Relation between food intake and visual analogue scale ratings of appetite and other sensations in healthy older and young subjects. Eur J Clin Nutr. 2004 Feb;58(2):212-8.</citation>
    <PMID>14749739</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 15, 2013</lastchanged_date>
  <firstreceived_date>November 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mount Sinai School of Medicine</investigator_affiliation>
    <investigator_full_name>Alice C. Levine</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>mild hypercortisolism</keyword>
  <keyword>Subclinical Cushing's Syndrome</keyword>
  <keyword>Preclinical Cushing's Syndrome</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
    <mesh_term>Cushing Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
